Skip to main content

News

News
04/03/2025
Jessica Garlewicz
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting nonalcoholic fatty liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting nonalcoholic fatty liver disease.
A new study examined 792,409...
04/03/2025
Gastroenterology
News
04/03/2025
Jessica Garlewicz
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response...
04/03/2025
Advances in Inflammatory Bowel Disease Network
FDA Alert
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
03/19/2025
Rebecca Mashaw
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of...
03/19/2025
Advances in Inflammatory Bowel Disease Network
News
03/17/2025
Jessica Garlewicz
Some patients in the open-label extension of TRUE NORTH required more time to respond, but efficacy appears durable up to 3 years.
Some patients in the open-label extension of TRUE NORTH required more time to respond, but efficacy appears durable up to 3 years.
Some patients in the open-label...
03/17/2025
Advances in Inflammatory Bowel Disease Network
News
03/17/2025
Jessica Garlewicz
One year after initiation, patients receiving upadacitinib were at significantly lower risk of colectomy than those treated with tofacitinib.
One year after initiation, patients receiving upadacitinib were at significantly lower risk of colectomy than those treated with tofacitinib.
One year after initiation,...
03/17/2025
Advances in Inflammatory Bowel Disease Network
News
03/14/2025
Jessica Garlewicz
Study findings highlight the importance of early diagnosis, improved treatment strategies, and equitable access to care for children affected by pediatric inflammatory bowel disease worldwide.
Study findings highlight the importance of early diagnosis, improved treatment strategies, and equitable access to care for children affected by pediatric inflammatory bowel disease worldwide.
Study findings highlight the...
03/14/2025
Advances in Inflammatory Bowel Disease Network
News
03/13/2025
Jessica Garlewicz
Surgical interventions are often essential when biologics alone prove inadequate in the treatment of fistulizing perianal Crohn's disease.
Surgical interventions are often essential when biologics alone prove inadequate in the treatment of fistulizing perianal Crohn's disease.
Surgical interventions are often...
03/13/2025
Advances in Inflammatory Bowel Disease Network
News
03/13/2025
Rebecca Mashaw
Adopting standardized measures and use of less invasive assessment methods should enhance patient monitoring.
Adopting standardized measures and use of less invasive assessment methods should enhance patient monitoring.
Adopting standardized measures...
03/13/2025
Advances in Inflammatory Bowel Disease Network
News
02/26/2025
Rebecca Mashaw
With mucosal healing now a primary goal of Crohn's disease (CD) treatment, investigators sought to compare the efficacy of novel therapies in achieving this goal in comparison to placebo.
With mucosal healing now a primary goal of Crohn's disease (CD) treatment, investigators sought to compare the efficacy of novel therapies in achieving this goal in comparison to placebo.
With mucosal healing now a...
02/26/2025
Advances in Inflammatory Bowel Disease Network